nach oben

Erschienen in:

22.02.2018 | Original Article

Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice

verfasst von: Concetta Panebianco, Kaarel Adamberg, Madis Jaagura, Massimiliano Copetti, Andrea Fontana, Signe Adamberg, Kaia Kolk, Raivo Vilu, Angelo Andriulli, Valerio Pazienza

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and aims

Pancreatic ductal adenocarcinoma (PDAC) represents the fourth cause of cancer-related death. We aimed to evaluate whether gemcitabine treatment shapes the gut microbiota in a model of PDAC xenografted mice.

Materials and methods

Pancreatic cancer xenograft mice were subjected to gemcitabine injection once per week for 3 weeks to assess the tumor volume as compared to control mice injected with normal saline solution. The composition of fecal microbiota, the activation of NF-kB pathway in cancer tissues and the serum metabolomics were further analyzed.

Results

Gemcitabine considerably decreases the proportion of Gram- positive Firmicutes (from about 39 to 17%) and the Gram- negative Bacteroidetes (from 38 to 17%) which are the two dominant phyla in the gut of tumor-bearing control mice. This downshift was replaced by an increase of Proteobacteria (Escherichia coli and Aeromonas hydrophila) from 15 up to 32% and Verrucomicrobia (Akkermansia muciniphila) from 5 to 33% in the gut of drug-receiving mice. An overall increase in inflammation-associated bacteria was observed upon gemcitabine. Consistently, activation of the NF-kB canonical pathway was found in cancer tissues from gemcitabine-treated mice. Serum metabolomics revealed a significant decrease of the purine compounds inosine and xanthine, and a decreasing trend for their metabolically-related molecule hypoxanthine.

Discussion

Understanding chemotherapy side effects may explain the lack of activity or the chemoresistant processes and it may help to set up strategies to improve the effectiveness of therapy.

Cid-Arregui A, Juarez V (2015) Perspectives in the treatment of pancreatic adenocarcinoma. World J Gastroenterol 21(31):9297–9316CrossRefPubMedPubMedCentral

Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, Marechal R, Van Laethem JL, Ducreux M (2016) Current standards and new innovative approaches for treatment of pancreatic cancer. Eur J Cancer 57:10–22CrossRefPubMed

Siegel RL, Miller KD, Jemal A, Cancer statistics (2016) CA Cancer. J Clin 66(1):7–30

Cheema AR, O’Reilly EM (2016) Management of Metastatic Pancreatic Adenocarcinoma. Surg Clin North Am 96(6):1391–1414CrossRefPubMed

D’Aronzo M, Vinciguerra M, Mazza T, Panebianco C, Saracino C, Pereira SP, Graziano P, Pazienza V (2015) Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models. Oncotarget 6(21):18545–18557PubMedPubMedCentral

Gharibi A, Adamian Y, Kelber JA (2016) Cellular and molecular aspects of pancreatic cancer. Acta Histochem 118(3):305–316CrossRefPubMedPubMedCentral

Korkeila EA (2015) Advanced pancreatic cancer—how to choose an adequate treatment option. World J Gastroenterol 21(38):10709–10713CrossRefPubMedPubMedCentral

Stathis A, Moore MJ (2010) Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 7(3):163–172CrossRefPubMed

Greer JB, Whitcomb DC (2009) Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 9(4):411–418CrossRefPubMed

10.

Steele CW, Kaur Gill NA, Jamieson NB, Carter CR (2016) Targeting inflammation in pancreatic cancer: clinical translation. World J Gastrointest Oncol 8(4):380–388CrossRefPubMedPubMedCentral

11.

Zambirinis CP, Pushalkar S, Saxena D, Miller G (2014) Pancreatic cancer, inflammation, and microbiome. Cancer J 20(3):195–202CrossRefPubMedPubMedCentral

12.

Momi N, Kaur S, Krishn SR, Batra SK (2012) Discovering the route from inflammation to pancreatic cancer. Minerva Gastroenterol Dietol 58(4):283–297PubMedPubMedCentral

13.

Uomo I, Miraglia S, Pastorello M (2010) Inflammation and pancreatic ductal adenocarcinoma: a potential scenario for novel drug targets. JOP 11(3):199–202PubMed

14.

Leal-Lopes C, Velloso FJ, Campopiano JC, Sogayar MC, Correa RG (2015) Roles of Commensal Microbiota in Pancreas Homeostasis and Pancreatic Pathologies. J Diabetes Res. https://doi.org/10.1155/2015/284680 PubMedPubMedCentral

15.

Schwabe RF, Jobin C (2013) The microbiome and cancer. Nat Rev Cancer 13(11):800–812CrossRefPubMedPubMedCentral

16.

Blaser MJ (2014) The microbiome revolution. J Clin Invest 124(10):4162–4165CrossRefPubMedPubMedCentral

17.

Zitvogel L, Galluzzi L, Viaud S, Vetizou M, Daillere R, Merad M, Kroemer G (2015) Cancer and the gut microbiota: an unexpected link. Sci Transl Med 7(271):271ps271CrossRef

18.

Panebianco C, Adamberg K, Adamberg S, Saracino C, Jaagura M, Kolk K, Di Chio AG, Graziano P, Vilu R, Pazienza V (2017) Engineered resistant-starch (ERS) diet shapes colon microbiota profile in parallel with the retardation of tumor growth in in vitro and in vivo pancreatic cancer models. Nutrients 9(4). https://doi.org/10.3390/nu9040331

19.

Farrell JJ, Zhang L, Zhou H, Chia D, Elashoff D, Akin D, Paster BJ, Joshipura K, Wong DT (2012) Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut 61(4):582–588CrossRefPubMed

20.

Michaud DS, Joshipura K, Giovannucci E, Fuchs CS (2007) A prospective study of periodontal disease and pancreatic cancer in US male health professionals. J Natl Cancer Inst 99(2):171–175CrossRefPubMed

21.

Touchefeu Y, Montassier E, Nieman K, Gastinne T, Potel G, Bruley des Varannes S, Le Vacon F, de La Cochetiere MF (2014) Systematic review: the role of the gut microbiota in chemotherapy- or radiation-induced gastrointestinal mucositis - current evidence and potential clinical applications. Aliment Pharmacol Ther 40(5):409–421PubMed

22.

Paglia G, Williams JP, Menikarachchi L, Thompson JW, Tyldesley-Worster R, Halldorsson S, Rolfsson O, Moseley A, Grant D, Langridge J, Palsson BO, Astarita G (2014) Ion mobility derived collision cross sections to support metabolomics applications. Anal Chem 86(8):3985–3993CrossRefPubMedPubMedCentral

23.

Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA (2005) Diversity of the human intestinal microbial flora. Science 308(5728):1635–1638CrossRefPubMedPubMedCentral

24.

Ley RE, Backhed F, Turnbaugh P, Lozupone CA, Knight RD, Gordon JI (2005) Obesity alters gut microbial ecology. Proc Natl Acad Sci USA 102(31):11070–11075CrossRefPubMedPubMedCentral

25.

Hausmann S, Kong B, Michalski C, Erkan M, Friess H (2014) The role of inflammation in pancreatic cancer. Adv Exp Med Biol 816:129–151CrossRefPubMed

26.

Kawai T, Akira S (2007) Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med 13(11):460–469CrossRefPubMed

27.

Christian F, Smith EL, Carmody RJ (2016) The regulation of NF-kappaB subunits by phosphorylation. Cells 5(1):12CrossRefPubMedCentral

28.

Clemente JC, Ursell LK, Parfrey LW, Knight R (2012) The impact of the gut microbiota on human health: an integrative view. Cell 148(6):1258–1270CrossRefPubMedPubMedCentral

29.

O’Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep 7(7):688–693CrossRefPubMedPubMedCentral

30.

Guinane CM, Cotter PD (2013) Role of the gut microbiota in health and chronic gastrointestinal disease: understanding a hidden metabolic organ. Ther Adv Gastroenterol 6(4):295–308CrossRef

31.

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI (2006) An obesity-associated gut microbiome with increased capacity for energy harvest. Nature 444(7122):1027–1031CrossRefPubMed

32.

Arthur JC, Perez-Chanona E, Muhlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA et al (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338(6103):120–123CrossRefPubMedPubMedCentral

33.

Shin NR, Whon TW, Bae JW (2015) Proteobacteria: microbial signature of dysbiosis in gut microbiota. Trends Biotechnol 33(9):496–503CrossRefPubMed

34.

Lavelle A, Lennon G, O’Sullivan O, Docherty N, Balfe A, Maguire A, Mulcahy HE, Doherty G, O’Donoghue D, Hyland J, Ross RP, Coffey JC, Sheahan K, Cotter PD, Shanahan F, Winter DC et al (2015) Spatial variation of the colonic microbiota in patients with ulcerative colitis and control volunteers. Gut 64(10):1553–1561CrossRefPubMedPubMedCentral

35.

Matsuoka K, Kanai T (2015) The gut microbiota and inflammatory bowel disease. Semin Immunopathol 37(1):47–55CrossRefPubMed

36.

Morgan XC, Tickle TL, Sokol H, Gevers D, Devaney KL, Ward DV, Reyes JA, Shah SA, LeLeiko N, Snapper SB, Bousvaros A, Korzenik J, Sands BE, Xavier RJ, Huttenhower C (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13(9):R79CrossRefPubMedPubMedCentral

37.

Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR (2007) Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA 104(34):13780–13785CrossRefPubMedPubMedCentral

38.

Ganesh BP, Klopfleisch R, Loh G, Blaut M (2013) Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLoS One 8(9):e74963CrossRefPubMedPubMedCentral

39.

Berry D, Schwab C, Milinovich G, Reichert J, Ben Mahfoudh K, Decker T, Engel M, Hai B, Hainzl E, Heider S, Kenner L, Muller M, Rauch I, Strobl B, Wagner M, Schleper C et al (2012) Phylotype-level 16S rRNA analysis reveals new bacterial indicators of health state in acute murine colitis. ISME J 6(11):2091–2106CrossRefPubMedPubMedCentral

40.

Vital M, Howe AC, Tiedje JM (2014) Revealing the bacterial butyrate synthesis pathways by analyzing (meta)genomic data. MBio 5(2):e00889CrossRefPubMedPubMedCentral

41.

Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ (2008) Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27(2):104–119CrossRefPubMed

42.

Canani RB, Costanzo MD, Leone L, Pedata M, Meli R, Calignano A (2011) Potential beneficial effects of butyrate in intestinal and extraintestinal diseases. World J Gastroenterol 17(12):1519–1528CrossRefPubMedPubMedCentral

43.

Chopin V, Toillon RA, Jouy N, Le Bourhis X (2002) Sodium butyrate induces P53-independent, Fas-mediated apoptosis in MCF-7 human breast cancer cells. Br J Pharmacol 135(1):79–86CrossRefPubMedPubMedCentral

44.

Gaschott T, Maassen CU, Stein J (2001) Tributyrin, a butyrate precursor, impairs growth and induces apoptosis and differentiation in pancreatic cancer cells. Anticancer Res 21(4A):2815–2819PubMed

45.

Scheppach W, Weiler F (2004) The butyrate story: old wine in new bottles? Curr Opin Clin Nutr Metab Care 7(5):563–567CrossRefPubMed

46.

Natoni F, Diolordi L, Santoni C, Gilardini Montani MS (2005) Sodium butyrate sensitises human pancreatic cancer cells to both the intrinsic and the extrinsic apoptotic pathways. Biochim Biophys Acta 1745(3):318–329CrossRefPubMed

47.

Blank-Porat D, Gruss-Fischer T, Tarasenko N, Malik Z, Nudelman A, Rephaeli A (2007) The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Lett 256(1):39–48CrossRefPubMed

48.

Ogawa H, Rafiee P, Fisher PJ, Johnson NA, Otterson MF, Binion DG (2003) Sodium butyrate inhibits angiogenesis of human intestinal microvascular endothelial cells through COX-2 inhibition. FEBS Lett 554(1–2):88–94CrossRefPubMed

49.

Zgouras D, Wachtershauser A, Frings D, Stein J (2003) Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1alpha nuclear translocation. Biochem Biophys Res Commun 300(4):832–838CrossRefPubMed

50.

Farrow B, Rychahou P, O’Connor KL, Evers BM (2003) Butyrate inhibits pancreatic cancer invasion. J Gastrointest Surg 7(7):864–870CrossRefPubMed

51.

van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced mucositis. PLoS Pathog 6(5):e1000879CrossRefPubMedPubMedCentral

52.

Yutin N, Galperin MY (2013) A genomic update on clostridial phylogeny: Gram-negative spore formers and other misplaced clostridia. Environ Microbiol 15(10):2631–2641PubMedPubMedCentral

53.

Bien J, Palagani V, Bozko P (2013) The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Therap Adv Gastroenterol 6(1):53–68CrossRefPubMedPubMedCentral

54.

Anand A, Glatt AE (1993) Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 17(1):109–113CrossRefPubMed

55.

Masciullo V, Mainenti S, Lorusso D, Margariti PA, Scambia G (2010) Lethal clostridium difficile colitis associated with paclitaxel and carboplatin chemotherapy in ovarian carcinoma: case report and review of the literature. Obstet Gynecol Int 2010:749789PubMedPubMedCentral

56.

Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ (2010) Clostridium difficile infection following chemotherapy. Recent Pat Antiinfect Drug Discov 5(1):1–9CrossRefPubMed

57.

Lin XB, Dieleman LA, Ketabi A, Bibova I, Sawyer MB, Xue H, Field CJ, Baracos VE, Ganzle MG (2012) Irinotecan (CPT-11) chemotherapy alters intestinal microbiota in tumour bearing rats. PLoS One 7(7):e39764CrossRefPubMedPubMedCentral

58.

Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Hamilton J, Keefe DM (2009) Gastrointestinal microflora and mucins may play a critical role in the development of 5-fluorouracil-induced gastrointestinal mucositis. Exp Biol Med (Maywood) 234(4):430–441CrossRef

59.

Montrose DC, Zhou XK, McNally EM, Sue E, Yantiss RK, Gross SS, Leve ND, Karoly ED, Suen CS, Ling L, Benezra R, Pamer EG, Dannenberg AJ (2016) Celecoxib alters the intestinal microbiota and metabolome in association with reducing polyp burden. Cancer Prev Res (Phila) 9(9):721–731CrossRef

60.

Forsgard RA, Marrachelli VG, Korpela K, Frias R, Collado MC, Korpela R, Monleon D, Spillmann T, Osterlund P (2017) Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague–Dawley rats. Cancer Chemother Pharmacol 80(2):317–332CrossRefPubMedPubMedCentral

61.

Daliri EB, Wei S, Oh DH, Lee BH (2017) The human microbiome and metabolomics: current concepts and applications. Crit Rev Food Sci Nutr 57(16):3565–3576CrossRefPubMed

62.

He B, Hoang TK, Wang T, Ferris M, Taylor CM, Tian X, Luo M, Tran DQ, Zhou J, Tatevian N, Luo F, Molina JG, Blackburn MR, Gomez TH, Roos S, Rhoads JM et al (2016) Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency-induced autoimmunity via adenosine A2A receptors. J Exp Med 214(1):107–123CrossRefPubMed

63.

da Rocha Lapa F, da Silva MD, de Almeida Cabrini D, Santos AR (2012) Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors. Purinergic Signal 8(4):693–704CrossRefPubMedPubMedCentral

64.

Hasko G, Kuhel DG, Nemeth ZH, Mabley JG, Stachlewitz RF, Virag L, Lohinai Z, Southan GJ, Salzman AL, Szabo C (2000) Inosine inhibits inflammatory cytokine production by a posttranscriptional mechanism and protects against endotoxin-induced shock. J Immunol 164(2):1013–1019CrossRefPubMed

65.

Gomez G, Sitkovsky MV (2003) Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood 102(13):4472–4478CrossRefPubMed

66.

Nguyen TL, Vieira-Silva S, Liston A, Raes J (2015) How informative is the mouse for human gut microbiota research? Dis Model Mech 8(1):1–16CrossRefPubMedPubMedCentral

Titel: Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice
verfasst von: Concetta Panebianco
Kaarel Adamberg
Madis Jaagura
Massimiliano Copetti
Andrea Fontana
Signe Adamberg
Kaia Kolk
Raivo Vilu
Angelo Andriulli
Valerio Pazienza
Publikationsdatum: 22.02.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Chemotherapy and Pharmacology / Ausgabe 4/2018
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3549-0

Neu im Fachgebiet Onkologie

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice

Abstract

Background and aims

Materials and methods

Results

Discussion

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background and aims

Materials and methods

Results

Discussion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer

Randomized phase II study of anastrozole plus tegafur-uracil as neoadjuvant therapy for ER-positive breast cancer in postmenopausal Japanese women (Neo-ACET BC)

Ibrutinib brain distribution: a preclinical study

FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

Combination of S-1 and gefitinib increases the sensitivity to radiotherapy in lung cancer cells

Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro

Neu im Fachgebiet Onkologie

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Stufenschema weist Prostatakarzinom zuverlässig nach

Update Onkologie